CLINICAL TRIALS PROFILE FOR GALLIUM NITRATE
✉ Email this page to a colleague
All Clinical Trials for Gallium Nitrate
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00002543 ↗ | Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors | Completed | National Cancer Institute (NCI) | Phase 1 | 1995-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: : Phase I trial to study the effectiveness of gallium nitrate in young patients who have malignant brain tumors, neuroblastoma, rhabdomyosarcoma, non-Hodgkin's lymphoma, or refractory solid tumor. |
NCT00002543 ↗ | Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors | Completed | Medical College of Wisconsin | Phase 1 | 1995-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: : Phase I trial to study the effectiveness of gallium nitrate in young patients who have malignant brain tumors, neuroblastoma, rhabdomyosarcoma, non-Hodgkin's lymphoma, or refractory solid tumor. |
NCT00002578 ↗ | Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma | Completed | National Cancer Institute (NCI) | Phase 2 | 1994-08-01 | RATIONALE: Chemotherapy uses different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gallium nitrate in treating patients with AIDS-related non-Hodgkin's lymphoma. |
NCT00002578 ↗ | Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma | Completed | Roswell Park Cancer Institute | Phase 2 | 1994-08-01 | RATIONALE: Chemotherapy uses different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gallium nitrate in treating patients with AIDS-related non-Hodgkin's lymphoma. |
NCT00054808 ↗ | Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma | Completed | Genta Incorporated | Phase 2 | 2002-06-01 | Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has progressed after standard chemotherapy. Patients will receive gallium nitrate 300 mg/m2/day by continuous IV infusion for 7 consecutive days using a portable infusion pump. Hospitalization is not required. Stable or responding patients will receive additional gallium nitrate infusions every 3 weeks until the time of disease progression, for a maximum total of 8 infusions, or 2 cycles after complete remission has been documented. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Gallium Nitrate
Condition Name
Clinical Trial Locations for Gallium Nitrate
Trials by Country
Clinical Trial Progress for Gallium Nitrate
Clinical Trial Phase
Clinical Trial Sponsors for Gallium Nitrate
Sponsor Name